Medtide Inc.

泰德医药(浙江)股份有限公司

03880.HK

Provides peptide-focused CRDMO services covering discovery, preclinical and clinical development, and commercial-stage production for biopharmaceutical clients. Ranked third largest peptide-focused CRDMO worldwide with 1.5% market share in 2023, per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Raw material and commodity prices
• Overseas markets and operations
• Key long-term agreements
• Backlog and project economics
• Capacity and utilisation
• Decline in revenue or profit
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Preferred shares and fair-value liabilities
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances